Polyclonal Antibody Articles & Analysis
11 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for food, feed, environmental and toxicological sample analysis, announces the availability of its high-quality Patulin Test Reagents. These reagents are suitable for assisting food producers and regulatory agencies in ensuring the safety of apples and apple-derived ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal ...
Fabentech, a pharmaceutical-stage biotechnology company specialized in the development, production and marketing of polyclonal antibodies for responding to emergency situations and treating emerging infectious diseases, today announced that it has been chosen to be a part of the COUNTERACT European consortium that is aiming to develop medical countermeasures to cope with CBRN threats. ...
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. This antibody is used for research only, not for human, therapeutic ...
The EPIC-CROWN-2 project, initiated by the Lyon-based biotech company, has received funding to the tune of 9.2 million euros from the European Commission. Thanks to this grant, awarded in the context of the first call for HERA projects (HERA is a new European authority dedicated to preparing and responding to health emergencies), Fab’entech will be able to accelerate the development of its ...
LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, announced today a collaborative agreement for the development, manufacture, and ...
Scientists now have realized that exosomes, representing a novel mode of intercellular communication, contribute to a wide range of biological processes in health and disease including cancer. Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer ...
Fab'entech, a French biotech specialised in the development and production of polyclonal antibodies, presents its new industrial site located in Saint-Priest, to the south-east of Lyon. The 1,000 m2 production site is now operational and will give Fab'entech the capacity to manufacture all of its innovations (biodefense and anti-COVID-19 programme: FabenCOV) in France. Close-up of this new site, ...
Fab’entech, a Lyon-based biopharmaceutical company specialised in immunotherapies for emergency situations, is today announcing the launch of a programme to develop an immunotherapy treatment against COVID-19. The treatment will be indicated in severely ill patients requiring respiratory assistance. The clinical trials are expected to begin in humans in 2021. In order to meet the new ...
Fab’entech, a Lyon-based biopharmaceutical company created in 2009 and specialised in immunotherapy for emergency situations, completes a new round of fundraising of 8.5 million euros led by Definvest, the fund of the Armed forces ministry managed by Bpifrance, with the participation of the Institut Mérieux and of its historical investors, Elaia, Sigma Gestion and Kreaxi – ...